Gianni, L., Pienkowski, T., Im, Y., Tseng, L., Liu, M., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G., & Valagussa, P. (n.d.). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet oncology, 17(6), 791–800. http://access.bl.uk/ark:/81055/vdc_100032476377.0x00003a